Hannah Johnston1, Emory R McTyre1, Cristina K Cramer1, Glenn J Lesser2, Jimmy Ruiz2, J Daniel Bourland1, Kounosuke Watabe3, Hui-Wen Lo3, Shadi Qasem4, Adrian W Laxton5, Stephen B Tatter5, Michael D Chan1. 1. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. 2. Department of Medicine (Hematology and Oncology), Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. 3. Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. 4. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. 5. Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Abstract
BACKGROUND: Brain metastases from gynecologic primary cancers are rare events, but they can be a cause of morbidity and mortality when they occur. METHODS: This is a single institution retrospective study on patients with brain metastases from gynecologic primary cancer who received Gamma Knife stereotactic radiosurgery (SRS). Between 2000 and 2013, a total of 33 patients with brain metastases from gynecologic primary including cervical (n=2), endometrial (n=6) and ovarian cancers (n=25) were treated with SRS at our institution. Electronic medical records were reviewed to determine survival, patterns of failure and cause of death. RESULTS: Overall survival at 1, 2 and 5 years for the entire population was 47.1%, 21.7%, and 14.5%, respectively. There was no difference in survival between the primary cancers (log-rank p = 0.33). 36.4% patients died of neurologic death. Local failure at 1 and 2 years for the entire population was 10.4% and 14.3%, respectively. There was no difference in local failure between the primary cancers. Distant brain failure at 1, 2 and 5 years for the entire population was 20.6%, 27.7%, and 31.3%, respectively. On multivariate Cox Proportional Hazards analysis, age was the only predictor of overall survival (HR = 1.03, p = 0.01). Ovarian cancer patients had decreased risk of distant brain failure (HR = 0.17, p=0.005), whereas cervical cancer patients had an increased risk of distant brain failure (HR = 35.7, p = 0.001). CONCLUSIONS: SRS represents a feasible treatment option for patients with brain metastases from gynecologic cancer. Younger age is a positive prognostic factor. Ovarian cancer patients have lower risk of distant brain failure.
BACKGROUND: Brain metastases from gynecologic primary cancers are rare events, but they can be a cause of morbidity and mortality when they occur. METHODS: This is a single institution retrospective study on patients with brain metastases from gynecologic primary cancer who received Gamma Knife stereotactic radiosurgery (SRS). Between 2000 and 2013, a total of 33 patients with brain metastases from gynecologic primary including cervical (n=2), endometrial (n=6) and ovarian cancers (n=25) were treated with SRS at our institution. Electronic medical records were reviewed to determine survival, patterns of failure and cause of death. RESULTS: Overall survival at 1, 2 and 5 years for the entire population was 47.1%, 21.7%, and 14.5%, respectively. There was no difference in survival between the primary cancers (log-rank p = 0.33). 36.4% patients died of neurologic death. Local failure at 1 and 2 years for the entire population was 10.4% and 14.3%, respectively. There was no difference in local failure between the primary cancers. Distant brain failure at 1, 2 and 5 years for the entire population was 20.6%, 27.7%, and 31.3%, respectively. On multivariate Cox Proportional Hazards analysis, age was the only predictor of overall survival (HR = 1.03, p = 0.01). Ovarian cancer patients had decreased risk of distant brain failure (HR = 0.17, p=0.005), whereas cervical cancer patients had an increased risk of distant brain failure (HR = 35.7, p = 0.001). CONCLUSIONS: SRS represents a feasible treatment option for patients with brain metastases from gynecologic cancer. Younger age is a positive prognostic factor. Ovarian cancer patients have lower risk of distant brain failure.
Authors: Desiree F Kolomainen; James M G Larkin; Mohammad Badran; Roger P A'Hern; D Michael King; Cyril Fisher; Jane E Bridges; Peter R Blake; Desmond P J Barton; John H Shepherd; Stanley B Kaye; Martin E Gore Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: J Sehouli; K Pietzner; P Harter; K Münstedt; S Mahner; A Hasenburg; O Camara; P Wimberger; D Boehmer; K J Buehling; R Richter; K El Khalfaoui; G Oskay-Ozcelik Journal: Ann Oncol Date: 2010-05-03 Impact factor: 32.976
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: G C Rodriguez; J T Soper; A Berchuck; J Oleson; R Dodge; G Montana; D L Clarke-Pearson Journal: J Clin Oncol Date: 1992-10 Impact factor: 44.544
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: S H J Nagtegaal; A F C Hulsbergen; E B L van Dorst; V K Kavouridis; C A C Jessurun; M L D Broekman; T R Smith; J J C Verhoeff Journal: Clin Transl Radiat Oncol Date: 2020-05-06